在早期帕金森病中,单氨基性退化,认知和自主性症状轨迹在早期帕金森病中
Seoyeon Kim1, Kyung Ah Woo1, Hongyoon Choi2
1Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Parkinsonism & related disorders
|August 8, 2024
概括
早期帕金森病 (PD) 脑干非多巴胺功能障碍与认知问题相关,并预测胃肠道症状恶化,突出潜在的非运动性进展标志物.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 帕金森病 (PD) 涉及与神经递质系统缺陷相关的非运动症状.
- 大脑干单氨基核,特别是血清和氨基核,都与此有关.
- 在早期的PD中研究这些核对于理解症状进展至关重要.
研究的目的:
- 检查认知/自主症状与脑干单氨基核退化在早期PD之间的关系.
- 为了确定帕金森病中非运动症状进展的预测因素.
主要方法:
- 对28名早期PD患者进行前性研究.
- [18F]FP-CIT PET扫描,MoCA和COMPASS-31在基线和3年后续的评估.
- 回归模型分析了非运动性症状相对于位置 (LC) 和拉菲变性.
主要成果:
- 基线LC和拉菲变性与较差的认知分数 (MoCA) 相关.
- 胃肠道症状在3年内恶化;认知得分保持稳定.
- 严重的LC/raphe退化预测加速胃肠道症状下降.
结论:
- 在早期的PD中,脑干非多巴胺功能障碍与认知缺陷有关.
- 这种功能障碍预测了胃肠道症状的进展.
- 非多巴胺基途径为非运动性PD进展提供了潜在的生物标志物.
相关概念视频
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108


